Swelling under the eyes months or even years after filler injection is a well-documented complication, not a sign that something has gone catastrophically wrong in a way nobody anticipated. The tear trough region is uniquely vulnerable to delayed puffiness because of its anatomy, its limited lymphatic drainage, and the way hyaluronic acid (HA) fillers interact with water over time. The causes range from the filler itself absorbing fluid and expanding to immune flare-ups triggered by an unrelated illness, and working out exactly which mechanism is responsible matters because the treatments differ.
Why the Under-Eye Area Is Uniquely Prone to Late Swelling
The skin beneath your eyes is among the thinnest on the body, and the fat and connective tissue underneath it are organized in a way that makes the area a poor host for injectable fillers compared to, say, the cheeks or lips. A dense sheet of fibrous tissue called the malar septum divides the fat beneath the lower eyelid into shallow and deep compartments. When filler is placed too shallowly relative to this septum, it can physically block the tiny lymphatic channels that normally drain fluid from the area. When it is placed deeper but in too large a volume, the filler can compress those same lymphatic vessels from below.
Either scenario slows the constant, subtle movement of fluid out of the under-eye region. Over weeks and months, that impaired drainage accumulates into visible puffiness that can look worse in the morning, after salty meals, or during allergy season, because all of those things temporarily increase fluid in a zone that can no longer clear it efficiently.
How Filler Absorbs Water and Expands Over Time
Hyaluronic acid is a molecule that loves water. Each HA molecule can bind many times its own weight in fluid, and that property is part of what makes HA fillers effective at plumping tissue. But it also means the filler does not simply sit inertly where it was placed. As the gel slowly breaks down, each remaining particle draws in water to compensate, a process sometimes called isovolumetric degradation. The total volume stays the same or even grows, even as the filler itself is being metabolized.
More hydrophilic (water-attracting) filler formulations are more prone to this effect. Products crosslinked with certain technologies tend to bind more water and have been linked to higher rates of persistent edema, particularly when placed superficially in the periorbital area.
MRI studies have confirmed something that surprises many patients and even some injectors: HA fillers can persist in the mid-face far longer than the 6 to 18 months typically quoted at the consultation. A review of 33 MRI cases found detectable HA in every patient scanned, including people who had not been injected for five, eight, or even fifteen years.
In a separate imaging study, one patient whose last injection was fifteen years earlier still had filler present, and it had expanded to roughly 3.5 times its original volume.
The Role of Filler Volume and Injection Technique
How much filler goes in matters as much as which product is used. In a large series of over 1,400 tear trough treatments, the volume injected was the strongest predictor of post-procedure edema, and anything over about 0.3 mL per side was significantly associated with swelling.
Injection technique also plays a role, though the evidence is less clear-cut. A prospective study comparing needle and cannula approaches to the tear trough found that patients reported less edema on the side treated with a needle and syringe compared to the cannula side immediately after the procedure.
The practical takeaway here is that the tear trough is a “less is more” zone. Conservative volumes with a less hydrophilic product, placed at the right depth, reduce the odds of waking up puffy months down the road. But even well-executed injections can produce delayed swelling because of the anatomical drainage issues described above, which means some risk is inherent to the location.
Immune Flare-Ups and Viral Triggers
One of the more unsettling causes of late swelling is an immune reaction triggered by something completely unrelated to the filler. Your immune system is always aware that there is a foreign material sitting under your skin. Most of the time it tolerates the filler quietly. But when the immune system gets activated by a viral infection, a vaccination, or even certain medications, it can mount a delayed inflammatory response at the filler site.
A systematic review of post-viral delayed inflammation at filler sites found a consistent pattern: immune activation from a viral exposure led to localized swelling, redness, or even significant facial puffiness at the exact location of a prior injection. The time between the viral trigger and the onset of swelling ranged from twelve hours to six weeks, suggesting that multiple immune pathways are involved.
This phenomenon gained public attention during the COVID-19 vaccination campaigns. A separate systematic review of swelling at filler sites after COVID-19 vaccination described it as a form of delayed-type hypersensitivity, driven by T cells that recognize the filler as a bystander target during the broader immune response. The estimated rate was low, around 0.02% of filler treatments, but the swelling could be dramatic enough to alarm patients who assumed their filler had been uneventful.
Flu-like illnesses, herpes simplex outbreaks, and gastrointestinal infections have all been associated with similar delayed reactions at filler sites. If you notice sudden under-eye puffiness after getting sick or getting a vaccine, and you had filler placed months or years earlier, this mechanism is a likely explanation.
Biofilm and Low-Grade Infection
Not all late swelling is caused by fluid dynamics or immune flare-ups. Bacteria can form a biofilm on the surface of filler material, creating a low-grade infection that simmers beneath the threshold of obvious symptoms for months before flaring up.
Biofilm-related complications typically show up as firm nodules under the skin, sometimes accompanied by mild tenderness, itching, or faint redness. A study of patients with delayed filler complications found that biofilm should be considered the likely cause when nodules appear three or more months after injection. The symptoms often follow a frustrating cycle: they improve temporarily with oral medication but return once the course is finished, because the biofilm itself remains intact on the filler surface.
Triggers that can cause a dormant biofilm to flare include other infections elsewhere in the body, hormonal changes around the menstrual cycle, mental stress, and acute illness. In that study, about two-thirds of patients had at least one recurring local symptom, and nearly a third had three or more.
Filler Migration
Filler does not always stay where it was placed. Gravity, muscle movement, and tissue pressure can cause the gel to shift over time, particularly in a mobile area like the lower eyelid where the orbicularis oculi muscle contracts with every blink. Case reports have documented filler migration presenting as eyelid swelling or as a noninflammatory lump near but not at the original injection site.
Migration is distinct from swelling caused by water absorption or immune activation, because the puffiness appears in a slightly different spot than where the filler was injected. It can be subtle enough that patients assume they are just retaining fluid, but imaging reveals a discrete mass of displaced material.
Granulomas Years After Injection
In rare cases, the body mounts a foreign-body granulomatous reaction to filler material, forming a firm mass of immune cells around the injected gel. Two reported cases involved patients who developed infraorbital masses roughly ten years after HA filler had been placed in their lower eyelids. Both patients had largely forgotten about the injections by the time the masses appeared; it was only after surgical removal and pathology examination that the connection was made.
Granulomas are not unique to HA fillers. A case report described deep-seated nodules on the cheeks of a patient eighteen months after poly-L-lactic acid (PLLA) filler injection, with biopsy confirming a foreign-body granuloma with non-caseating granulomas in the dermis.
These reactions are uncommon, but they underscore that any injectable filler, regardless of the material, can provoke an immune response long after the procedure.
How to Figure Out What Is Causing the Swelling
When you show up at a clinic with under-eye puffiness months after filler, the first challenge is figuring out which of the mechanisms above is responsible, because the treatments are quite different.
High-frequency ultrasound with color Doppler has emerged as the first-line imaging tool for evaluating filler complications. It can identify the type of filler present, its exact location and depth, whether it has migrated, and whether there are signs of infection. Under ultrasound, HA filler typically appears as a clear, cyst-like or striated structure with well-defined borders. If the filler has diffused into surrounding tissue, the normal tissue layers look blurred and disorganized. Blood flow within the area suggests infection, and bright spots with acoustic shadowing suggest calcification.
MRI can also detect filler and is especially useful for assessing volume and spread when ultrasound is inconclusive. But ultrasound is faster, cheaper, and can be done in the office, which is why it has become the go-to first step.
Dissolving the Filler With Hyaluronidase
For HA-based fillers, hyaluronidase is the enzyme that breaks the filler down. It is the most direct solution when the swelling is caused by the filler material itself, whether from water absorption, impaired lymphatic drainage, or simple overfilling.
A study of patients presenting with periorbital HA complications found that the average time between filler injection and seeking treatment was about 26 months, with some patients waiting up to six years. The complications included persistent edema, bulging along the tear trough, undercorrection, and subcutaneous nodules. Using a high-dose approach of 150 to 600 units per lower eyelid in a single session, all patients responded successfully.
Hyaluronidase works well for problems caused by the filler itself, but it will not resolve swelling driven by an immune reaction or a biofilm infection. If the underlying issue is inflammation rather than excess material, dissolving the filler can actually help by removing the target the immune system is reacting to, but it often needs to be combined with other treatments.
Treating Infection and Inflammatory Nodules
When biofilm is the suspected cause, the treatment approach shifts to antibiotics, sometimes for extended courses. An expert consensus recommended empiric antibiotic regimens that include combinations like clarithromycin plus moxifloxacin for ten days, ciprofloxacin for two to four weeks, or minocycline for up to six months.
For late-onset inflammatory nodules more broadly, a global consensus outlined a ladder of interventions. Oral antibiotics and oral steroids are typically the first step. If those are insufficient, options include nonsteroidal anti-inflammatory drugs, hyaluronidase (for non-inflammatory HA nodules), intralesional antibiotics, intralesional immunosuppressive drugs such as steroids or fluorouracil, and, as a last resort, surgical excision.
The key distinction for patients is that not every lump or puffiness responds to the same treatment. A firm, tender nodule that keeps coming back after antibiotics stop may need filler dissolution, intralesional treatment, or removal. Soft, diffuse morning puffiness that worsens with salt intake is more likely a drainage problem that responds to hyaluronidase or time.
The Blue Tint That Is Not Quite What You Think
Some patients notice a bluish discoloration under the eyes after filler, which is commonly attributed to the Tyndall effect, a term from physics describing how light scatters through colloidal solutions. The name has stuck in dermatology, but it is technically a misnomer. HA fillers are large, irregularly shaped, crosslinked hydrogels, nothing like the uniform spherical particles that produce true Tyndall scattering. The skin itself also filters out blue wavelengths at shallow depths, making it unlikely that blue light generated at the level of the filler would be visible to an outside observer.
What patients are actually seeing is likely a combination of the filler’s translucency interacting with the skin’s own optical properties and the thinness of under-eye skin revealing the filler beneath it. More hydrophilic fillers placed superficially are more prone to this discoloration. Whether you call it the Tyndall effect or not, the clinical implication is the same: it signals that the filler is sitting too shallowly and may benefit from dissolution or deeper replacement.
When Swelling Is Not From the Filler at All
Delayed under-eye puffiness in someone who has had filler is not automatically the filler’s fault. Allergies, thyroid dysfunction, kidney issues, and normal aging changes in the fat pads around the eyes can all produce swelling that coincidentally appears in the same area. Before assuming the filler is the problem, it is worth getting a proper evaluation that includes imaging to confirm whether filler material is still present and whether it has changed in volume or position. Patients who had filler placed years ago and forgotten about it can be especially tricky, as the case reports of granulomas appearing a decade later illustrate. If imaging shows filler in an area you do not remember being treated, the material has either migrated or was placed longer ago than you recall.
Ultrasound can distinguish between filler-related swelling and other causes quickly, which is why requesting imaging rather than accepting a visual-only assessment is reasonable if you are unsure. The under-eye area is small, the stakes for your appearance are high, and the treatment for filler-related edema is very different from the treatment for, say, allergic puffiness or thyroid-related fluid retention.